Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort

LEADS Consortium; Angelina J. Polsinelli; Ryan J. Wonderlin; Dustin B. Hammers; Alex Pena Garcia; Ani Eloyan; Alexander Taurone; Maryanne Thangarajah; Laurel Beckett; Sujuan Gao; Sophia Wang; Kala Kirby; Paige E. Logan; Paul Aisen; Jeffrey L. Dage; Tatiana Foroud; Percy Griffin; Leonardo Iaccarino; Joel H. Kramer; Robert Koeppe; Walter A. Kukull; Renaud La Joie; Nidhi S. Mundada; Melissa E. Murray; Kelly Nudelman; David N. Soleimani-Meigooni; Malia Rumbaugh; Arthur W. Toga; Alexandra Touroutoglou; Prashanthi Vemuri; Alireza Atri; Gregory S. Day; Ranjan Duara; Neill R. Graff-Radford; Lawrence S. Honig; David T. Jones; Joseph Masdeu; Mario F. Mendez; Kyle Womack; Erik Musiek; Chiadi U. Onyike; Meghan Riddle; Emily Rogalski; Steven Salloway; Sharon J. Sha; Raymond S. Turner; Thomas S. Wingo; David A. Wolk; Maria C. Carrillo; Bradford C. Dickerson; Gil D. Rabinovici; Liana G. Apostolova

doi:10.1002/alz.13344

Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort

LEADS Consortium, Angelina J. Polsinelli, Ryan J. Wonderlin, Dustin B. Hammers, Alex Pena Garcia, Ani Eloyan, Alexander Taurone, Maryanne Thangarajah, Laurel Beckett, Sujuan Gao, Sophia Wang, Kala Kirby, Paige E. Logan, Paul Aisen, Jeffrey L. Dage, Tatiana Foroud, Percy Griffin, Leonardo Iaccarino, Joel H. Kramer, Robert KoeppeWalter A. Kukull, Renaud La Joie, Nidhi S. Mundada, Melissa E. Murray, Kelly Nudelman, David N. Soleimani-Meigooni, Malia Rumbaugh, Arthur W. Toga, Alexandra Touroutoglou, Prashanthi Vemuri, Alireza Atri, Gregory S. Day, Ranjan Duara, Neill R. Graff-Radford, Lawrence S. Honig, David T. Jones, Joseph Masdeu, Mario F. Mendez, Kyle Womack, Erik Musiek, Chiadi U. Onyike, Meghan Riddle, Emily Rogalski, Steven Salloway, Sharon J. Sha, Raymond S. Turner, Thomas S. Wingo, David A. Wolk, Maria C. Carrillo, Bradford C. Dickerson, Gil D. Rabinovici, Liana G. Apostolova

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Introduction: We examined neuropsychiatric symptoms (NPS) and psychotropic medication use in a large sample of individuals with early-onset Alzheimer's disease (EOAD; onset 40-64 years) at the midway point of data collection for the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Methods: Baseline NPS (Neuropsychiatric Inventory – Questionnaire; Geriatric Depression Scale) and psychotropic medication use from 282 participants enrolled in LEADS were compared across diagnostic groups – amyloid-positive EOAD (n = 212) and amyloid negative early-onset non-Alzheimer's disease (EOnonAD; n = 70). Results: Affective behaviors were the most common NPS in EOAD at similar frequencies to EOnonAD. Tension and impulse control behaviors were more common in EOnonAD. A minority of participants were using psychotropic medications, and use was higher in EOnonAD. Discussion: Overall NPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants. Future research will investigate moderators and etiological drivers of NPS, and NPS differences in EOAD versus late-onset AD.

Original language	English
Pages (from-to)	S42-S48
Journal	Alzheimer's and Dementia
Volume	19
Issue number	S9
DOIs	https://doi.org/10.1002/alz.13344
State	Published - Nov 2023

Keywords

early-onset Alzheimer's disease
early-onset dementia
mild cognitive impairment
neuropharmacology
neuropsychiatric symptoms
psychotropic medications

Access to Document

10.1002/alz.13344

Cite this

LEADS Consortium, Polsinelli, A. J., Wonderlin, R. J., Hammers, D. B., Garcia, A. P., Eloyan, A., Taurone, A., Thangarajah, M., Beckett, L., Gao, S., Wang, S., Kirby, K., Logan, P. E., Aisen, P., Dage, J. L., Foroud, T., Griffin, P., Iaccarino, L., Kramer, J. H., ... Apostolova, L. G. (2023). Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort. Alzheimer's and Dementia, 19(S9), S42-S48. https://doi.org/10.1002/alz.13344

@article{9fddaff2a89342aba0754e664368235f,

title = "Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort",

abstract = "Introduction: We examined neuropsychiatric symptoms (NPS) and psychotropic medication use in a large sample of individuals with early-onset Alzheimer's disease (EOAD; onset 40-64 years) at the midway point of data collection for the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Methods: Baseline NPS (Neuropsychiatric Inventory – Questionnaire; Geriatric Depression Scale) and psychotropic medication use from 282 participants enrolled in LEADS were compared across diagnostic groups – amyloid-positive EOAD (n = 212) and amyloid negative early-onset non-Alzheimer's disease (EOnonAD; n = 70). Results: Affective behaviors were the most common NPS in EOAD at similar frequencies to EOnonAD. Tension and impulse control behaviors were more common in EOnonAD. A minority of participants were using psychotropic medications, and use was higher in EOnonAD. Discussion: Overall NPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants. Future research will investigate moderators and etiological drivers of NPS, and NPS differences in EOAD versus late-onset AD.",

keywords = "early-onset Alzheimer's disease, early-onset dementia, mild cognitive impairment, neuropharmacology, neuropsychiatric symptoms, psychotropic medications",

author = "{LEADS Consortium} and Polsinelli, {Angelina J.} and Wonderlin, {Ryan J.} and Hammers, {Dustin B.} and Garcia, {Alex Pena} and Ani Eloyan and Alexander Taurone and Maryanne Thangarajah and Laurel Beckett and Sujuan Gao and Sophia Wang and Kala Kirby and Logan, {Paige E.} and Paul Aisen and Dage, {Jeffrey L.} and Tatiana Foroud and Percy Griffin and Leonardo Iaccarino and Kramer, {Joel H.} and Robert Koeppe and Kukull, {Walter A.} and {La Joie}, Renaud and Mundada, {Nidhi S.} and Murray, {Melissa E.} and Kelly Nudelman and Soleimani-Meigooni, {David N.} and Malia Rumbaugh and Toga, {Arthur W.} and Alexandra Touroutoglou and Prashanthi Vemuri and Alireza Atri and Day, {Gregory S.} and Ranjan Duara and Graff-Radford, {Neill R.} and Honig, {Lawrence S.} and Jones, {David T.} and Joseph Masdeu and Mendez, {Mario F.} and Kyle Womack and Erik Musiek and Onyike, {Chiadi U.} and Meghan Riddle and Emily Rogalski and Steven Salloway and Sha, {Sharon J.} and Turner, {Raymond S.} and Wingo, {Thomas S.} and Wolk, {David A.} and Carrillo, {Maria C.} and Dickerson, {Bradford C.} and Rabinovici, {Gil D.} and Apostolova, {Liana G.}",

note = "Publisher Copyright: {\textcopyright} 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.",

year = "2023",

month = nov,

doi = "10.1002/alz.13344",

language = "English",

volume = "19",

pages = "S42--S48",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

number = "S9",

}

LEADS Consortium, Polsinelli, AJ, Wonderlin, RJ, Hammers, DB, Garcia, AP, Eloyan, A, Taurone, A, Thangarajah, M, Beckett, L, Gao, S, Wang, S, Kirby, K, Logan, PE, Aisen, P, Dage, JL, Foroud, T, Griffin, P, Iaccarino, L, Kramer, JH, Koeppe, R, Kukull, WA, La Joie, R, Mundada, NS, Murray, ME, Nudelman, K, Soleimani-Meigooni, DN, Rumbaugh, M, Toga, AW, Touroutoglou, A, Vemuri, P, Atri, A, Day, GS, Duara, R, Graff-Radford, NR, Honig, LS, Jones, DT, Masdeu, J, Mendez, MF, Womack, K , Musiek, E, Onyike, CU, Riddle, M, Rogalski, E, Salloway, S, Sha, SJ, Turner, RS, Wingo, TS, Wolk, DA, Carrillo, MC, Dickerson, BC, Rabinovici, GD & Apostolova, LG 2023, 'Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort', Alzheimer's and Dementia, vol. 19, no. S9, pp. S42-S48. https://doi.org/10.1002/alz.13344

Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort. / LEADS Consortium; Polsinelli, Angelina J.; Wonderlin, Ryan J. et al.
In: Alzheimer's and Dementia, Vol. 19, No. S9, 11.2023, p. S42-S48.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort

AU - LEADS Consortium

AU - Polsinelli, Angelina J.

AU - Wonderlin, Ryan J.

AU - Hammers, Dustin B.

AU - Garcia, Alex Pena

AU - Eloyan, Ani

AU - Taurone, Alexander

AU - Thangarajah, Maryanne

AU - Beckett, Laurel

AU - Gao, Sujuan

AU - Wang, Sophia

AU - Kirby, Kala

AU - Logan, Paige E.

AU - Aisen, Paul

AU - Dage, Jeffrey L.

AU - Foroud, Tatiana

AU - Griffin, Percy

AU - Iaccarino, Leonardo

AU - Kramer, Joel H.

AU - Koeppe, Robert

AU - Kukull, Walter A.

AU - La Joie, Renaud

AU - Mundada, Nidhi S.

AU - Murray, Melissa E.

AU - Nudelman, Kelly

AU - Soleimani-Meigooni, David N.

AU - Rumbaugh, Malia

AU - Toga, Arthur W.

AU - Touroutoglou, Alexandra

AU - Vemuri, Prashanthi

AU - Atri, Alireza

AU - Day, Gregory S.

AU - Duara, Ranjan

AU - Graff-Radford, Neill R.

AU - Honig, Lawrence S.

AU - Jones, David T.

AU - Masdeu, Joseph

AU - Mendez, Mario F.

AU - Womack, Kyle

AU - Musiek, Erik

AU - Onyike, Chiadi U.

AU - Riddle, Meghan

AU - Rogalski, Emily

AU - Salloway, Steven

AU - Sha, Sharon J.

AU - Turner, Raymond S.

AU - Wingo, Thomas S.

AU - Wolk, David A.

AU - Carrillo, Maria C.

AU - Dickerson, Bradford C.

AU - Rabinovici, Gil D.

AU - Apostolova, Liana G.

PY - 2023/11

Y1 - 2023/11

N2 - Introduction: We examined neuropsychiatric symptoms (NPS) and psychotropic medication use in a large sample of individuals with early-onset Alzheimer's disease (EOAD; onset 40-64 years) at the midway point of data collection for the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Methods: Baseline NPS (Neuropsychiatric Inventory – Questionnaire; Geriatric Depression Scale) and psychotropic medication use from 282 participants enrolled in LEADS were compared across diagnostic groups – amyloid-positive EOAD (n = 212) and amyloid negative early-onset non-Alzheimer's disease (EOnonAD; n = 70). Results: Affective behaviors were the most common NPS in EOAD at similar frequencies to EOnonAD. Tension and impulse control behaviors were more common in EOnonAD. A minority of participants were using psychotropic medications, and use was higher in EOnonAD. Discussion: Overall NPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants. Future research will investigate moderators and etiological drivers of NPS, and NPS differences in EOAD versus late-onset AD.

AB - Introduction: We examined neuropsychiatric symptoms (NPS) and psychotropic medication use in a large sample of individuals with early-onset Alzheimer's disease (EOAD; onset 40-64 years) at the midway point of data collection for the Longitudinal Early-onset Alzheimer's Disease Study (LEADS). Methods: Baseline NPS (Neuropsychiatric Inventory – Questionnaire; Geriatric Depression Scale) and psychotropic medication use from 282 participants enrolled in LEADS were compared across diagnostic groups – amyloid-positive EOAD (n = 212) and amyloid negative early-onset non-Alzheimer's disease (EOnonAD; n = 70). Results: Affective behaviors were the most common NPS in EOAD at similar frequencies to EOnonAD. Tension and impulse control behaviors were more common in EOnonAD. A minority of participants were using psychotropic medications, and use was higher in EOnonAD. Discussion: Overall NPS burden and psychotropic medication use were higher in EOnonAD than EOAD participants. Future research will investigate moderators and etiological drivers of NPS, and NPS differences in EOAD versus late-onset AD.

KW - early-onset Alzheimer's disease

KW - early-onset dementia

KW - mild cognitive impairment

KW - neuropharmacology

KW - neuropsychiatric symptoms

KW - psychotropic medications

UR - http://www.scopus.com/inward/record.url?scp=85163140267&partnerID=8YFLogxK

U2 - 10.1002/alz.13344

DO - 10.1002/alz.13344

M3 - Article

C2 - 37296082

AN - SCOPUS:85163140267

SN - 1552-5260

VL - 19

SP - S42-S48

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - S9

ER -

Baseline neuropsychiatric symptoms and psychotropic medication use midway through data collection of the Longitudinal Early-Onset Alzheimer's Disease Study (LEADS) cohort

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this